Equity Overview
Price & Market Data
Price: $1.30
Daily Change: -$0.055 / 4.25%
Range: $1.27 - $1.35
Market Cap: $148,412,176
Volume: 289,664
Performance Metrics
1 Week: 17.68%
1 Month: 52.93%
3 Months: -1.79%
6 Months: -59.05%
1 Year: -71.23%
YTD: -20.84%
Company Details
Employees: 181
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.